Aurinia Pharmaceuticals Inc. Selling, General and Administrative Expense
Aurinia Pharmaceuticals Inc. (AUPH) reported Selling, General and Administrative Expense of $195.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-02-15
- Aurinia Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2023 was $195.00M, a 0.71% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2022 was $196.40M, a 13.20% increase from fiscal 2021.
- Aurinia Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2021 was $173.50M, a 78.31% increase from fiscal 2020.
- Aurinia Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2020 was $97.30M, a 336.32% increase from fiscal 2019.
| Period end | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|
| 2023-12-31 | $195.00M 10-K · filed 2024-02-15 | |
| 2022-12-31 | $196.40M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $173.50M 10-K · filed 2024-02-15 | $171.40M 10-K · filed 2022-02-28 |
| 2020-12-31 | $97.30M 10-K · filed 2023-02-28 | $96.00M 10-K · filed 2022-02-28 |
| 2019-12-31 | $22.30M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |